+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating KB801, a special virus-based treatment designed to deliver human nerve growth factor to the corneas of people with Stage 2 or 3 neurotrophic keratitis, a condition that affects corneal healing. This Phase 12 study is designed to assess the safety, tolerability, and early signs of effectiveness of KB801 compared to a placebo. The study is double-masked and placebo-controlled, involving participants with persistent corneal epithelial defects that have not improved. Participants will be randomly assigned to receive either KB801 or a placebo, applied topically to the affected eye once daily for 8 weeks. After completing treatment, they will return for a follow-up visit two weeks later to check on safety and the stability of corneal healing. Further safety monitoring will take place every three months for about one year while participants remain in the study. Throughout the trial, participants will undergo regular assessments to monitor safety, including tracking any adverse events. Researchers will evaluate healing of the corneal defects using specific measurements over 8 to 10 weeks. Safety follow-up visits extend through approximately one year to observe the durability of treatment effects and overall tolerability. Participants can expect regular visits for examinations and safety monitoring during this time.

Age: 18Years +All GendersPhase 1Phase 2
9 locations
E

Actively Recruiting

Researchers are conducting a Phase 2 randomized, double-masked, vehicle-controlled study to evaluate the safety and effectiveness of DFL24498 topical ophthalmic solution compared to a vehicle solution in adults with dry eye disease. Approximately 417 participants aged 18 years or older will be enrolled across multiple sites in the US. The study aims to understand how the treatment affects dry eye symptoms and eye health over 16 weeks. Participants will be randomly assigned to receive either DFL24498 or a vehicle solution, both administered as one drop in each eye four times daily for 12 weeks. The study includes three periods within the total 16 weeks, including treatment and follow-up phases. The treatments are applied topically to the eyes under controlled conditions to compare their effects. During the study, participants will undergo assessments such as corneal fluorescein staining using the National Eye Institute scale, symptom evaluations with the Symptom Assessment in Dry Eye questionnaire, tear production tests, and conjunctival staining. Safety will be monitored through reports of adverse events up to week 14. Visual acuity and other ocular measurements will be regularly checked to monitor treatment impact and participant health throughout the study.

Age: 18Years +All GendersPhase 2
24 locations
O

Actively Recruiting

Researchers are conducting an observational study to track the natural history, clinical course, and management patterns of people with limbal stem cell deficiency LSCD. The study focuses on participants aged 12 to 99 years who have a diagnosis of LSCD. It aims to understand how this condition progresses over time by assessing changes in vision and eye structure without administering any study treatments. Participants will not receive any study drug or product as this is a non-interventional study. Instead, researchers will observe and collect information on the conditions progression and management. The study will follow participants from screening through 84 weeks, monitoring various vision-related and anatomical changes that are associated with LSCD. During the study, participants will undergo regular assessments including patient-reported outcomes and multiple vision tests such as photophobic best corrected visual acuity BCVA, low-luminance BCVA, low-contrast BCVA, and contrast sensitivity. Anatomical changes will also be evaluated through eye examinations over the 84-week period. Researchers will track both functional and structural changes to better understand LSCDs impact and progression in the study population.

Age: 12Years - 99YearsAll Genders
8 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of EO2002, an investigational magnetic human corneal endothelial cell therapy, in adults with corneal edema caused by corneal endothelial dysfunction. The study compares two doses of EO2002 against a placebo injection to assess their impact on vision and corneal thickness. This Phase 2 trial is randomized and double-masked, involving about 105 participants at multiple sites in the United States. Participants will receive a single intracameral injection of EO2002 at either 150,000 or 500,000 magnetic human corneal endothelial cells, or a placebo injection with no cells. The study follows participants for 52 weeks, monitoring changes in best-corrected visual acuity and central corneal thickness to evaluate treatment effects and safety. During the study, participants will have regular assessments to monitor vision and corneal thickness, along with safety evaluations over the 52-week follow-up. Researchers will measure best-corrected visual acuity at 26 weeks as the primary outcome. Participants will be observed through scheduled visits to track treatment effects and any side effects throughout the trial duration.

Age: 21Years +All GendersPhase 2
10 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of an investigational eye drop called CSB-001 Ophthalmic Solution 0.1% in adults with recent corneal scars caused by various eye injuries or conditions that occurred within the past 7 to 30 days. This Phase 1 study focuses on scars located near the center of the cornea that affect vision, aiming to understand how well the treatment works and how safe it is for participants. All participants will receive CSB-001 starting on Day 1, dosing either four times daily or three times daily in the affected eye for up to 14 days. If a participants scar has resolved by Day 7, they will stop treatment but continue follow-up visits. Scheduled visits occur on Days 14, 21, 28, 56, and at Month 3 to monitor progress and safety. Participants will have safety assessments including eye exams with slit-lamp biomicroscopy and vision tests from screening through Day 56. Researchers will also measure scar size, depth, volume, density, contrast sensitivity, and distance vision to evaluate the treatments effects. The study includes careful monitoring for any side effects and lasts about three months for each participant.

Age: 18Years - 80YearsAll GendersPhase 1
7 locations
O

Actively Recruiting

This research aims to evaluate the safety and effectiveness of CSB-001 Ophthalmic Solution 0.1% in people with limbal stem cell deficiency LSCD. It is an open-label Phase 1 study sponsored by Claris Biotherapeutics, Inc. Participants will receive the investigational drug in one or both eyes to investigate its impact on this eye condition. The study includes two dosing phases separated by a break and a long-term follow-up period. Participants will receive one drop of CSB-001 four times daily during two 8-week dosing periods separated by a 31- to 40-day dosing holiday where no drug is given. These dosing phases are followed by an observational phase lasting up to Week 48. After this, participants may choose to join an additional 36-month observational extension phase to Week 144. The study is non-randomized and open-label, meaning all participants receive the study drug. During the study, participants will be assessed regularly for safety using adverse event reporting, slit-lamp biomicroscopy, and vision tests through Week 144. Effectiveness will be measured by changes in LSCD stage and vision clarity. Study visits will include clinical examinations and eye imaging. Safety and vision will be monitored throughout the treatment and observation periods to understand the drugs impact over time.

Age: 18Years +All GendersPhase 1
6 locations